Mesenkia Therapeutics AB
PrivateLast Round
VC Round
May 22, 2026
Total Funding Raised
$590,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Mesenkia Therapeutics AB is a biotechnology company that develops biological drug candidates for the treatment of glioblastoma.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mesenkia Therapeutics AB Comparables
Compare Mesenkia Therapeutics AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adaptin Bio | 81% | |
| Targepeutics | 79% | |
| Merck & Co., Inc. | 69% |
Mesenkia Therapeutics AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 22, 2026 | ||||
| Seed | Jun 2, 2025 |
Mesenkia Therapeutics AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Almi Invest AB | Seed |
| Uppsala University Invest | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 24, 2026
Grew 60% from 5 to 8 employees this quarter.
- May 22, 2026
Raised a VC Round with participation from lsi-zeta.
Recent news
Latest coverage and updates
- partners_withAug 19, 2026
Mesenkia Therapeutcs AB partnered with BioArctic AB on Aug 19th '26.
- is_developingAug 19, 2026
Mesenkia Therapeutcs AB is developing novel antibody-based approach for glioblastoma on Aug 19th '26.
Mesenkia Therapeutics AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Mesenkia Therapeutics AB's valuation, stock price, and market status.
Is Mesenkia Therapeutics AB a public or private company?
Mesenkia Therapeutics AB is a private company.
What is the current stock price of Mesenkia Therapeutics AB?
Mesenkia Therapeutics AB is a private company with no public stock price. Caplight tracks Mesenkia Therapeutics AB's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Mesenkia Therapeutics AB worth (valuation)?
Valuation information for Mesenkia Therapeutics AB is not publicly available.
Can I buy Mesenkia Therapeutics AB stock?
Mesenkia Therapeutics AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Mesenkia Therapeutics AB's last funding round?
Mesenkia Therapeutics AB's most recent funding round was VC Round on May 22, 2026.
Who are the main investors in Mesenkia Therapeutics AB?
Key investors in Mesenkia Therapeutics AB include Almi Invest AB, Uppsala University Invest.
Will Mesenkia Therapeutics AB IPO soon?
No public IPO plans have been announced for Mesenkia Therapeutics AB.
How can I track Mesenkia Therapeutics AB secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mesenkia Therapeutics AB's secondary market activity and sign up for updates.